PP
PTGX icon

PDT Partners’s Protagonist Therapeutics PTGX Stock Holding History

PDT Partners’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-81,835
Closed -$893K – 690
2022
Q4 		$893K Sell
81,835
-44,203
-35% -$373K 0.14% 256
2022
Q3 		$1.06M Buy
126,038
+37,460
+42% +$354K 0.16% 203
2022
Q2 		$701K Buy
88,578
+72,610
+455% +$878K 0.06% 511
2022
Q1 		$378K Sell
15,968
-50
-0.3% -$1.41K 0.03% 648
2021
Q4 		$548K Sell
16,018
-13,682
-46% -$432K 0.04% 506
2021
Q3 		$526K Buy
+29,700
New +$1.27M 0.04% 466
2020
Q2 		– Sell
-31,421
Closed -$222K – 790
2020
Q1 		$222K Sell
31,421
-11,985
-28% -$89.8K 0.02% 539
2019
Q4 		$306K Buy
43,406
+23,785
+121% +$236K 0.02% 536
2019
Q3 		$236K Buy
19,621
+4,610
+31% +$58.1K 0.01% 397
2019
Q2 		$182K Buy
+15,011
New +$166K 0.01% 373
2018
Q1 		– Sell
-30,266
Closed -$630K – 597
2017
Q4 		$630K Buy
30,266
+4,366
+17% +$77.5K 0.02% 403
2017
Q3 		$458K Buy
25,900
+8,500
+49% +$118K 0.02% 439
2017
Q2 		$197K Sell
17,400
-600
-3% -$6.42K 0.01% 484
2017
Q1 		$231K Buy
+18,000
New +$290K 0.01% 436

Other funds holding PTGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PDT Partners's PTGX Position: Q1 2023 in Review

PDT Partners sold out of Protagonist Therapeutics (PTGX) in Q1 2023, closing a stake of 81,835 shares — an estimated $893K sold.

PDT Partners first reported a position in PTGX in Q1 2017 and held it in 14 quarters. The position peaked at $1.06M in Q3 2022. 137 funds tracked by Wall St. Rank hold PTGX as of Q1 2023.

  • PDT Partners reported no remaining Protagonist Therapeutics position as of Q1 2023 after selling out during the quarter.
  • PDT Partners sold 81,835 Protagonist Therapeutics shares in Q1 2023, an estimated $893K.
  • PDT Partners first reported a position in Protagonist Therapeutics in Q1 2017 and held it in 14 quarters.
  • PDT Partners's Protagonist Therapeutics position peaked at $1.06M in Q3 2022.
  • 137 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2023.

Based on PDT Partners's 13F filing for Q1 2023, filed 15 May 2023.